訊聯生技集團創立於1999年，以「再生醫學/細胞治療」、「精準健康/基因醫學」、「分子數位科技/智慧研發」三大核心能力，成為亞洲最具國際代表性的生技品牌。旗下「訊聯生技」(2007年-台灣第一家專攻細胞治療上市櫃公司)、「訊聯基因(原名:創源生技)」(2012年-台灣第一家專攻基因醫學及科學資訊上市櫃公司)，已服務全台超過51%新生兒、90%婦產專科醫院及生殖醫學中心，拓展至海外17國，總客戶達150萬人次。 訊聯通過衛福部核准特管法細胞治療，包括脂肪間質幹細胞用於退化性關節炎、膝關節軟骨缺損、慢性傷口，以及免疫細胞CIK治療大腸直腸癌、肺癌、乳癌、肝癌等多種癌症。並持續拓展再生醫學及細胞治療應用範圍、精進醫美保養品/毛髮生長開發、Exosome等細胞衍生物及細胞製程的品質與技術。2022年更成立「訊聯細胞智藥股份有限公司」，加速開發再生醫療細胞製劑、外泌體Exosome的診斷與治療，並結合智慧研發、優異的基因和細胞療法開發技術、數位模擬創新能力，提供更廣大服務。 BIONET Corp. was established in 1999 as the pioneer company in the field of precision health and regenerative medicine in Taiwan. In 2007, BIONET successfully completed initial public offering (IPO) and became the first publicly traded company in the stem cell and genetic testing industry of Taiwan. The Genetics Generation Advancement Corporation (GGA Corp.) is a subsidiary of BIONET. In 2012, GGA became the first publicly traded company in Taiwan to specialize in genetic testing and scientific informatics. BIONET Group focuses in three areas: Cell Therapy、Precision Health / Genetic Medicine and Scientific Informatics- providing cells, genetic testing, skin care products and other technologies. BIONET serves more than 51% of newborns, 90% of gynecology / obstetrics clinics and reproductive medicine centers in Taiwan while expanding services to 17 countries overseas; meeting the health needs of more than 1.5 million customers at different stages in life. To date, BIONET received several cell therapy approvals from the Ministry of Health and Welfare under the special management regulation , including adipose-derived mesenchymal stem cell treatment for degenerative arthritis, knee cartilage defects, chronic wounds, and immune cell (CIK) treatment of colorectal cancer, lung cancer, breast cancer, liver cancer and other cancers. Furthermore, BIONET also expand the application scope of regenerative medicine and cell therapy, medical and skin care products/hair growth development, cell derivatives such as Exosomes, and cell processing. In 2022, BIONET Group established new company "BIONET Therapeutics Corp." which combines smart research and development, gene and cell therapy development technology, and digital simulation innovation capabilities to provide broader services.